Advertisement

Potential Therapeutic Use of BDNF or NT-4/5 in Parkinson’s and Alzheimer’s Diseases

  • C. Anthony Altar
  • Ralph F. Alderson
  • Keith D. Anders
  • Carolyn Hyman
  • Stanley J. Wiegand
  • Ronald M. Lindsay
Part of the Advances in Behavioral Biology book series (ABBI, volume 44)

Abstract

A growing body of evidence has revealed that the neuropathologies of Parkinson’s and Alzheimer’s diseases reflect numerous system atrophies, rather than singular deficits of ldopaminergic or cholinergic neurons, respectively (see Agid et al, 1987 and Reisberg, 1983 for reviews). Both diseases can eventually result in losses of catecholaminergic, indoleaminergic, cholinergic, and peptidergic neurons but vary in the degree to which these cell groups are affected, particularly at early stages. Research efforts have focused on the identification of common mechanisms contributing to these conditions, as well as determinations of growth factor responsiveness of the affected neuronal populations. The present report summarizes in vitro and in vivo evidence that two members of the neurotrophin family of growth factors, brain-derived neurotrophic factor (BDNF) and neurotrophin-4/5 (NT-4/5), support the survival or maturation of phenotypic markers in rat neuronal populations that correspond to those severely affected in Parkinson’s and Alzheimer’s diseases. BDNF also promotes the expression of at least several of the neuropeptides that are also decreased in Alzheimer’s disease (Nawa et al, 1993; Croll et al, 1993). The present review, however, will survey the more extensive information currently available for the in vivo and in vitro actions of BDNF or NT-4/5 on monoaminergic, cholinergic, and GABAergic neurotransmitters.

Keywords

Brain Derive Neurotrophic Factor Cholinergic Neuron Dopamine Neuron GABAergic Neuron Glutamic Acid Decarboxylase 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Agid, Y., Javoy-Agid, F., and Ruberg, M., 1992, Biochemistry of Neurotransmitters in Parkinson’s Disease, in: Movement Disorders 2, C.D. Marsden and S. Fahn, eds. Butterworths„ pp. 166–230.Google Scholar
  2. Alderson, R. F, Alterman, A.., Morissey, D., and Lindsay, R. M., 1993, Effects of NT-4/5, BDNF, or NGF on the survival and phenotypic differentiation of septal cholinergic neurons in long-term cultures, Soc. Neurosci. Abstr. 19: 666.Google Scholar
  3. Altar, C. A., Boylan, C. B., Jackson, C., Hershenson, S., Miller, J., Wiegand, S.J., Lindsay, R. M., and Hyman, C., 1992, Brain-derived neurotrophic factor augments rotational behavior and nigrostriatal dopamine turnover in vivo, Proc. Natl. Acad. Sci. (USA) 89: 11347–11351.CrossRefGoogle Scholar
  4. Altar, C. A., Criden, M. R., Lindsay, R. M., and DiStefano, P. S., 1993, Characterization and topography of high affinity VI]neurotrophin-3 binding to mammalian brain, J. Neurosci. 13: 733–743.PubMedGoogle Scholar
  5. Altar, C.A., Siuciak, J., Boylan, C., Fritsche, M., Wiegand, S. J., Alderson, R.F. and Lindsay, R.M., 1993b, Effects of BDNF and NT-3 on serotonin, dopamine, and acetylcholine neurons in vivo, J. Neurochem. 61 ( Suppl. ): S7C.Google Scholar
  6. Altar, C. A., Boylan, C.B., Fritsche, M., Jones, B.E., Jackson, C., Wiegand, S.J., Lindsay, R.M., and Hyman, C. BDNF and NT-3 ameliorate neurochemical and behavioral deficits associated with partial nigrostriatal dopamine lesions, J. Neurochem. (Submitted).Google Scholar
  7. Altar, C. A., Siuciak, J. A., Wright, P., Ip, N.Y., Lindsay, R.M. and Wiegand, S.J. In situ hybridization of trkB and trkC receptor mRNA in rat forebrain and association with [’uI]NT-3, F° I]BDNF, and [’2I]NT-4/5 binding atoradiography, Eur. J. Neurosci. (Submitted)Google Scholar
  8. Anderson, K. D., Alderson, R.F., Altar, C.A., DiStefano, P.S., Lindsay, R.M., and Wiegand, S.J., 1993, Distribution of exogenous BDNF and NGF delivered into the brain, Soc. Neurosci. Abstr. 19: 662.Google Scholar
  9. Beck, K, Knúsel, B, and Hefti, F., 1993, The nature of the trophic action of brain-derived neurotrophic factor, des(1–3)-insulin-like growth factor-1, and basic fibroblast growth factor on mesencephalic dopaminergic neurons developing in culture, Neuroscience 52: 855–866.PubMedCrossRefGoogle Scholar
  10. Collazo, D., Takahashi, H., and McKay, R.D.G., 1992, Cellular targets and trophic functions of neurotrophin-3 in the developing rat hippocampus, Neuron 9: 643–656.PubMedCrossRefGoogle Scholar
  11. Croll, S.D., Wiegand, S.J., Anderson, K.D., Lindsay, R.M., and Nawa, H., 1993, Neuropeptide regulation by BDNF and NGF in adult rat forebrain, Soc. Neurosci. Abstr. 19: 662.Google Scholar
  12. Friedman, W.J., Ibanez, C.F., Hallbröök, F., Persson, H., Cain, L.D., Dreyfus, C.F., and Black, I.B., 1993, Differential actions of neurotrophins in the locus coeruleus and basel forebrain, Exp. Neurol., 119: 72–78.PubMedCrossRefGoogle Scholar
  13. Gai, W.P., Geffen L. B., Deneroy L., and Blessing W. W., 1993, Loss of C1 and C3 epinephrinesynthesizing neurons in the medulla oblongata in parkinson’s disease, Ann. Neurol. 33: 357–367.PubMedCrossRefGoogle Scholar
  14. Goedert, M., Fine, A., Hunt, S.P., and Ullrich, A., 1986, Nerve growth factor mRNA in peripheral and central rat tissues and in the human central nervous system: Lesion effects in the rat brain and levels in Alzheimer’s disease, Mol. Brain Res. 1: 85–92.CrossRefGoogle Scholar
  15. Glass, D. J., and Yancopoulos, G. D., 1993, The neurotrophins and their receptors, Trends Cell Biol., 3: 262–268.PubMedCrossRefGoogle Scholar
  16. Hallböök, F., Ibanez, C.F., and Perssön, H., 1991, Evolutionary studies of the nerve growth factor family reveal a novel member abundantly expressed in xenopus ovary, Neuron 6: 247–252.CrossRefGoogle Scholar
  17. Hyman, C., Hofer, M., Barde, Y-A., Juhasz, M., Yancopoulos, G.D., Squinto, S P, and Lindsay, R.M., 1991a, BDNF is a neurotrophic factor for dopaminergic neurons of the substantia nigra, Nature 350: 230–232.PubMedCrossRefGoogle Scholar
  18. Hyman, C., Juhasz, M., Jackson, C., Radziejewski, C., and Lindsay, R.M., 1991b, Effects of BDNF and NT-3 on dopamiergic and GABAergic neurons in rat ventral mesencephalic cultures, Soc. Neurosci. Abstr. 17: 908.Google Scholar
  19. Hyman, C., Juhasz, M, Jackson, C., Wright, P., Ip, N.Y., and Lindsay, R.M., 1994, Overlapping and distinct actions of the neurotrophins BDNF, NT-3, and NT-4/5 on cultured dopaminergic and GABAergic neurons of the ventral mesencephalon, J. Neurosci. (in press).Google Scholar
  20. Iacopino, A.M., and Christakos, S., 1990, Specific reduction of calcium binding protein (28-kilodalton calbindin-D) gene expression in aging and neurodegenerative diseases, Proc. Natl. Acad. Sci. USA, 87: 4078–4082.PubMedCrossRefGoogle Scholar
  21. Ip, N.Y., Ibanez, C.F., Nye, S.H., McClain, J., Jones, P.F., Gies, D.R., Belluscio, L., Beau, M.M.L., III, R.E., Squinto, S.P., Perssön, H., and Yancopoulos, G., 1992, Mammalian neurotrophin-4: structure, chromosomal localization, tissue distribution and receptor specificity, Proc Natl. Acad. Sci. USA 89: 3060–3064.CrossRefGoogle Scholar
  22. Ip, N.Y., Stitt, T.N., Tapley, P., Klein, R., Glass, D.J., Fandl, J., Greene, L.A., Barbacid, M., and Yancopoulos, G. D., 1993a, Similarities and differences in the way neurotrophins interact with the Trk receptors in neuronal and nonneuronal cells, Neuron 10: 137–149.PubMedCrossRefGoogle Scholar
  23. Ip, N.Y., Yanping, L., Yancopoulos, G. D. and Lindsay, R.M., 1993b, Cultured hippocampal neurons show responses to BDNF, NT-3, and NT-4/5 but not NGF, J. Neurosci. 13: 3394–3405.PubMedGoogle Scholar
  24. Knüsel, B., Winslow, J., Rosenthal, A., Burton, L.E., Seid, D.P., Nikolics, L. and Hefti, F., 1991, Promotion of central cholinergic and dopaminergic neuron differentiation by brain-derived neurotrophic facor but not neurotrophin-3, Proc. Natl. Acad. Sci. USA 88: 961–965.PubMedCrossRefGoogle Scholar
  25. Knüsel, B., Beck, D.D., Winslow, J.W., Rosenthal, A., Burton, L.E., Windmer, H.R., Nikolics, K., and Hefti, F., 1992, Brain-derived neurotrophic factor administration protects basal forebrain cholinergic but not dopaminergic neurons from degenerative changes after axotomy in the adult brain, J. Neurosci. 12: 4391–4402.PubMedGoogle Scholar
  26. Lârkfors, L., Ebendal, T., Lindsay, R.M., and Alderson, R.F., 1993, Effects of neurotrophins on rat embryonic cerebellar purkinje cells in vitro, Soc. Neurosci. Abstr. 19: 667.Google Scholar
  27. Lindsay, R.M., Altar, C.A., Cedarbaum, J., Hyman, C., and Wiegand, S.J., 1993, Neurotrophic factors in the treatment of Parkinson’s Disease, J.E. Springer, ed. Exp. Neurol. 124:103–118.Google Scholar
  28. Martin-Iverson, M.T., Todd, K.G., and Altar, C.A., 1994, Behavioral and in vivo neurochemical effects of the neurotrophic factors BDNF and NT-3 and their interactions with amphetamine. J. Neurosci. 14: 1262–1270.PubMedGoogle Scholar
  29. Merlio, J.P., Ernfors, P., Jaber, M., and Persson, H., 1992, Molecular cloning of rat trkC and distribution of cells expressing messenger RNAs for members of the trk family in the rat central nervous system, Neuroscience 51: 513–532.PubMedCrossRefGoogle Scholar
  30. Morse, J.K., Wiegand, S.J., Anderson, K.A., You, Y., Cai, N., DiStefano, P.S., Altar, C.A., Lindsay, R.M., and Alderson, R.F., 1993, Brain derived neurotrophic factor (BDNF) increases the survival of basal forebrain cholinergie neurons following a fimbria-fornix transection, J. Neurosci. 13: 4146–4156.PubMedGoogle Scholar
  31. Nawa, H., Bessho, Y., Carnahan, J. H., Nakanishi, S., and Mizuno, K., 1993, Regulation of neuropeptide expression in cultured cerebral cortical neurons by brain-derived neurotrophic factor, J. Neurochem. 60: 772–775.PubMedCrossRefGoogle Scholar
  32. Phillips, H.S., Hains, J.M., Armanini, M., Laramee, G.R., Johnson, S.A, and Winslow, J.W., 1991, BDNF mRNA is decreased in the hippocampus of individuals with Alzheimer’s Disease, Neuron 7: 695–702.PubMedCrossRefGoogle Scholar
  33. Reisberg, B., 1983, Alzheimer’s Disease, ed. Free Press, New York.Google Scholar
  34. Sauer, H.F., Nikkah, W. G., Wiegand, S.J., Brundin, P., Lindsay, R.M., and Bjorklund, A., 1993, Brain-derived neurotrophic factor enhances function rather than survival of intrastriatal dopamine cell-rich grafts, Brain Res.Google Scholar
  35. Shen, R., Altar, C.A., and Chiodo, L.A., 1993, Chronic supranigral infusion of BDNF increases the electrophysiological activity of pars compacta dopamine neurons, Soc. Neurosci. Abstr. 19: 654.Google Scholar
  36. Siuciak, J.A., Altar, C.A., Wiegand, S.M. and Lindsay, R.M., 1994, Antinociceptive effects of brainderived neurotrophic factor and neurotrophin-3. Brain Res. 633: 326–330.PubMedCrossRefGoogle Scholar
  37. Spenger, C., Stromberg, I., Studer, L., and Seiler, R., 1992, BDNF increases TH-immunoreactivity in human fetal ventral mesencephalic neurons in an organotypic culture, Soc. Neurosci. Abstr. 18: 226.Google Scholar
  38. Spina, M.B., Squinto, S.P., Miller, J., Lindsay, R.M., and Hyman, C., 1992, Brain-derived neurotrophic factor protects dopamine neurons against 6-hydroxydopamine and n-methyl-4-phenylpyridinium ion toxicity:involvement of the glutathione system, J. Neurochem. 59: 99–106.PubMedCrossRefGoogle Scholar
  39. Stewart, S.S., and Appel, S.H., 1988, Trophic factors in neurologic disease, Annu. Rev. Med. 39: 193–201.PubMedCrossRefGoogle Scholar
  40. Ventimiglia, R., Mather, P., and Lindsay, R.M., 1993, Brain-derived neurotrophic factor promotes survival and biochemical and morphological differentiation of striatal GABA neurons in vitro, Soc. Neurosci. Abstr. 19: 666.Google Scholar
  41. Wiegand, S.J., Alexander, C., Lindsay, R.M., and DiStefano, P.S., 1991, Axonal transport of [’’I]-labeled neurotrophins in the central nervous system, Soc. Neurosci. Abstr. 17: 1121.Google Scholar
  42. Wiegand, S.J., Alexander, C., Jackson, C., Anderson, K.D., Lindsay, R.M., Altar, C.A., and Hyman, C., 1993, BDNF ameliorates amphetamine-induced rotational asymmetry in hemi-Parkinsonian rats, Soc. Neurosci. Abstr. 19: 1681.Google Scholar

Copyright information

© Springer Science+Business Media New York 1995

Authors and Affiliations

  • C. Anthony Altar
    • 1
  • Ralph F. Alderson
    • 1
  • Keith D. Anders
    • 1
  • Carolyn Hyman
    • 1
  • Stanley J. Wiegand
    • 1
  • Ronald M. Lindsay
    • 1
  1. 1.Regeneron PharmaceuticalsTarrytownUSA

Personalised recommendations